Document Detail


Use of CA-125 response to predict survival parameters of patients with advanced ovarian carcinoma.
MedLine Citation:
PMID:  7941993     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The prognostic value of serum CA-125 levels both before chemotherapy and after each cycle of one or two courses was assessed in 48 patients with advanced ovarian adenocarcinoma. All patients received a minimum of six courses of either cyclophosphamide and cisplatinum (CP) or cyclophosphamide, doxorubicin and cisplatinum (CAP). Patients with serum CA-125 values below the normal value of 35 U/ml after two courses had a significantly longer median survival (p < 0.0001) and longer disease-free survival (p = 0.007) than did those patients whose CA-125 levels dropped to normal after the third or a later course of chemotherapy. A response in CA-125 levels after the first two courses of chemotherapy may indicate which patients should continue with the current chemotherapy regimen and which patients should be offered salvage therapy.
Authors:
I G Ron; M Inbar; I Gelernter; O Lewysohn; D Ayalon; J Dale; S Chaitchik
Related Documents :
20619633 - Preoperative plasma timp-1 is an independent prognostic indicator in patients with prim...
6889963 - Lactosylsphingosine-reactive antibody and cea in patients with colorectal cancer.
16488713 - Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Acta obstetricia et gynecologica Scandinavica     Volume:  73     ISSN:  0001-6349     ISO Abbreviation:  Acta Obstet Gynecol Scand     Publication Date:  1994 Sep 
Date Detail:
Created Date:  1994-11-01     Completed Date:  1994-11-01     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  0370343     Medline TA:  Acta Obstet Gynecol Scand     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  658-62     Citation Subset:  IM    
Affiliation:
Department of Oncology, Tel-Aviv Sourasky Medical Center, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy,  immunology*,  pathology
Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
CA-125 Antigen / immunology*
Cisplatin / therapeutic use
Cyclophosphamide / therapeutic use
Female
Humans
Middle Aged
Ovarian Neoplasms / drug therapy,  immunology*,  pathology
Prognosis
Chemical
Reg. No./Substance:
0/CA-125 Antigen; 15663-27-1/Cisplatin; 50-18-0/Cyclophosphamide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The relationship of clinical-pathologic status and adjuvant treatment with natural killer cell activ...
Next Document:  Non-traumatic rupture of kidney in pregnancy--case report and review.